ZCM
EGRX

Zebra Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Zebra Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,472
Closed -$277K – 220
2021
Q2 		$277K Sell
6,472
-698
-10% -$28.8K 0.32% 112
2021
Q1 		$299K Buy
+7,170
New +$333K 0.33% 110

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Zebra Capital Management's EGRX Position: Q3 2021 in Review

Zebra Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2021, closing a stake of 6,472 shares — an estimated $277K sold.

Zebra Capital Management first reported a position in EGRX in Q1 2021 and held it in 2 quarters. The position peaked at $299K in Q1 2021. 151 funds tracked by Wall St. Rank hold EGRX as of Q3 2021.

  • Zebra Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Zebra Capital Management sold 6,472 Eagle Pharmaceuticals, Inc. shares in Q3 2021, an estimated $277K.
  • Zebra Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2021 and held it in 2 quarters.
  • Zebra Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $299K in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2021.

Based on Zebra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.